
(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Africa's energy giants eye long-term gains on Iran war disruption - 2
Nine in 10 German industrial firms expect Iran war to hit business - 3
Space debris: will it take a catastrophe for nations to take the issue seriously? - 4
Vote in favor of Your #1 4\u00d74 SUVs - 5
Indian Health Service is digging out of decades-old construction backlog for medical buildings
Man threatens attack on German high-speed train, injures several
Figure out How to Acquire Rewarding Open Record Rewards
Top 15 Supportable Design Brands Coming out on top
As infant botulism cases climb to 31, recalled ByHeart baby formula is still on some store shelves
The Best Design Bloggers for Style Motivation
An Extended time of Careful Nurturing: Individual Bits of knowledge on Bringing up Kids
Doctored NXT Summit footage falsely portrays Modi as declaring war on Iran and Pakistan
What's the Fate of 5G Innovation?
How to sound like an astronaut as you follow the first human moon mission in more than half a century













